<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00980330</url>
  </required_header>
  <id_info>
    <org_study_id>CR016063</org_study_id>
    <secondary_id>TMC435-TiDP16-C206</secondary_id>
    <secondary_id>2009-010590-20</secondary_id>
    <nct_id>NCT00980330</nct_id>
  </id_info>
  <brief_title>A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment</brief_title>
  <acronym>ASPIRE</acronym>
  <official_title>A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Efficacy, Tolerability, Safety and Pharmacokinetics of TMC435 as Part of a Treatment Regimen Including PegIFNa-2a and Ribavirin in HCV Genotype 1 Infected Subjects Who Failed Previous Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tibotec Pharmaceuticals, Ireland</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tibotec Pharmaceuticals, Ireland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy, safety and tolerability of different
      regimens of TMC435 with standard treatment compared to standard treatment alone in
      participants with chronic, genotype 1, hepatitis C virus (HCV) infection who has failed
      previous treatment with pegylated interferon (Peg-INF-alfa-2a) and ribavirin (RBV).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized (study drug assigned by chance), double-blind (neither physician
      nor participant knows the name of the assigned drug), placebo-controlled Phase IIb trial with
      TMC435 in participants with chronic, genotype 1, hepatitis C virus (HCV) infection who have
      failed standard treatment with pegylated interferon (Peg-INF-alfa-2a) and ribavirin (RBV).
      The study will compare the efficacy, tolerability and safety of different regimens with
      TMC435 combined with standard treatment (Peg-INF-alfa-2a and RBV) versus standard treatment
      alone. The trial will consist of a screening period of maximum 6 weeks, a 48-week treatment
      period, and a 24-week follow-up period. Participants will be eligible to enroll in the trial
      if they failed to respond to a prior course of standard treatment or relapsed following
      standard treatment. Participants will be randomly assigned to receive TMC435 with standard
      treatment for 12 weeks followed by standard treatment (plus placebo) for 36 weeks, TMC435
      (100 mg or 150 mg once a day) with standard treatment for 24 weeks followed by standard
      treatment (plus placebo) for 24 weeks, TMC435 (100 mg or 150 mg once a day) with standard
      treatment for 48 weeks, or a placebo with standard treatment for 48 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage of Participants Achieving a Sustained Virologic Response at the End of Treatment (EOT) and 24 Weeks After the EOT (SVR24)</measure>
    <time_frame>Week 72</time_frame>
    <description>The table below shows the percentage of participants in the overall population with an SVR24, defined as having plasma levels of Hepatitis C Virus ribonucleic acid less than 25 IU/mL undetectable at the EOT and 24 weeks after the EOT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Participants With a Greater Than 2 log10 Drop in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Time Points During Treatment</measure>
    <time_frame>Weeks, 2, 4, 8, and 12</time_frame>
    <description>The table below shows the percentage of participants in each treatment group who achieved a greater than 2 log10 drop in plasma levels of HCV RNA at selected time points during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Participants Achieving Plasma Levels of Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Undetectable During Treatment and Follow-up</measure>
    <time_frame>Weeks, 2, 4, 8, 12, 24, 36, 48, 60, 72 and EOT (up to Week 48)</time_frame>
    <description>The table below shows the percentage of participants in each treatment who achieved plasma HCV RNA levels of &lt;25 IU/mL undetectable at selected time points during treatment and follow-up and at the end of treatment (EOT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Participants Achieving Plasma Levels of Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Detectable or Undetectable During Treatment and Follow-up</measure>
    <time_frame>Weeks, 2, 4, 8, 12, 24, 36, 48, 60, 72, and EOT (up to Week 48)</time_frame>
    <description>The table below shows the percentage of participants in each treatment group who achieved plasma HCV RNA levels below the limit of quantification defined as less than 25 IU/mL (detectable or undetectable) at selected time points during treatment, follow-up, and at the end of treatment (EOT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Participants Achieving a Rapid Virologic Response (RVR)</measure>
    <time_frame>Week 4</time_frame>
    <description>The table below shows the percentage of participants in each treatment group who achieved a RVR, defined as having an undetectable plasma Hepatitis C virus ribonucleic acid level after receiving 4 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Participants Achieving an Early Virologic Response (EVR)</measure>
    <time_frame>Week 12</time_frame>
    <description>The table below shows the percentage of participants who achieved an EVR, defined as having a greater than or equal to 2 log10 reduction in plasma Hepatitis C virus ribonucleic acid from baseline at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)</measure>
    <time_frame>Week 12</time_frame>
    <description>The table below shows the percentage of participants in each treatment group who had a cEVR, defined as having undetectable plasma levels of Hepatitis C virus ribonucleic acid at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)</measure>
    <time_frame>Week 60</time_frame>
    <description>The table below shows the percentage of participants in the overall population who achieved undetectable plasma Hepatitis C virus ribonucleic acid levels at the end of treatment (EOT) and 12 Weeks after the planned EOT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Participants With Viral Breakthrough</measure>
    <time_frame>EOT (up to Week 48)</time_frame>
    <description>The table below shows the percentage of participants in the overall population in each treatment group during the treatment period who experienced viral breakthrough, defined as a confirmed increase of greater than 1 log10 IU/mL in Hepatitis C virus (HCV) ribonucleic acid (RNA) from the lowest level reached or a confirmed HCV RNA of &gt; 100 IU/mL in participants whose HCV RNA had previously been below the lower limit of quantification (i.e., less than 25 IU/mL detectable or undetectable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Participants With Viral Relapse</measure>
    <time_frame>Up to Week 72</time_frame>
    <description>The table below shows the percentage of participants in the overall population who had viral relapse, defined as confirmed detectable Hepatitis C virus (HCV) ribonucleic acid (RNA) during the follow-up period in participants with HCV RNA less than 25 IU/mL undetectable at end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants Who Achieved Normalized Alanine Aminotransferase (ALT) Levels at the End of Treatment (EOT)</measure>
    <time_frame>EOT (up to Week 48)</time_frame>
    <description>The table below shows the number of participants with abnormal ALT levels at Baseline who achieved the normal ALT levels at the EOT (up to Week 48).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of TMC435</measure>
    <time_frame>0 (predose, baseline) and 4, 8, 12, and 24 hours post-dose at Weeks 2, 4, 8, 12, 16, 24, and 48</time_frame>
    <description>The table below shows median (range) predose plasma concentration (C0h) values and median (range) average steady-state plasma concentration (Css,av) values for TMC435 for participants in each of the 6 TMC435 treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24h) for TMC435</measure>
    <time_frame>0 (predose, baseline) and 4, 8, 12, and 24 hours post-dose at Weeks 2, 4, 8, 12, 16, 24, and 48</time_frame>
    <description>The table below shows the median (range) AUC24h values for TMC435 for participants in each TMC435 treatment group.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">463</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>TMC435 100 mg 12 Wks + PR48</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo with PR for 36 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMC435 100 mg 24 Wks + PR48</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants willl receive TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed by Placebo with PR for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMC435 100 mg 48 Wks + PR48</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMC435 150 mg 12 Wks + PR48</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo and PR for 36 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMC435 150 mg 24 Wks + PR48</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed Placebo and PR for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMC435 150 mg 48 Wks + PR48</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 48 Wks + PR48</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive Placebo once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMC435</intervention_name>
    <description>One TMC435 100-mg capsule or two 75-mg capsules orally (by mouth) once daily for 12, 24, or 48 weeks.</description>
    <arm_group_label>TMC435 100 mg 12 Wks + PR48</arm_group_label>
    <arm_group_label>TMC435 100 mg 24 Wks + PR48</arm_group_label>
    <arm_group_label>TMC435 100 mg 48 Wks + PR48</arm_group_label>
    <arm_group_label>TMC435 150 mg 12 Wks + PR48</arm_group_label>
    <arm_group_label>TMC435 150 mg 24 Wks + PR48</arm_group_label>
    <arm_group_label>TMC435 150 mg 48 Wks + PR48</arm_group_label>
    <arm_group_label>Placebo 48 Wks + PR48</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One or 2 capsules of placebo identical in appearance to TMC435 taken orally once daily for 24, 36, or 48 weeks.</description>
    <arm_group_label>TMC435 100 mg 12 Wks + PR48</arm_group_label>
    <arm_group_label>TMC435 100 mg 24 Wks + PR48</arm_group_label>
    <arm_group_label>TMC435 100 mg 48 Wks + PR48</arm_group_label>
    <arm_group_label>TMC435 150 mg 12 Wks + PR48</arm_group_label>
    <arm_group_label>TMC435 150 mg 24 Wks + PR48</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peg-IFN-alfa-2a (P)</intervention_name>
    <description>180 micrograms taken as one 0.5 mL subcutaneous injection once weekly for 48 weeks.</description>
    <arm_group_label>TMC435 100 mg 12 Wks + PR48</arm_group_label>
    <arm_group_label>TMC435 100 mg 24 Wks + PR48</arm_group_label>
    <arm_group_label>TMC435 100 mg 48 Wks + PR48</arm_group_label>
    <arm_group_label>TMC435 150 mg 12 Wks + PR48</arm_group_label>
    <arm_group_label>TMC435 150 mg 24 Wks + PR48</arm_group_label>
    <arm_group_label>TMC435 150 mg 48 Wks + PR48</arm_group_label>
    <arm_group_label>Placebo 48 Wks + PR48</arm_group_label>
    <other_name>PEGASYS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (R)</intervention_name>
    <description>1000 or 1200 mg/day (5 or 6 tablets) taken orally as a twice daily regimen taken for 48 weeks.</description>
    <arm_group_label>TMC435 100 mg 12 Wks + PR48</arm_group_label>
    <arm_group_label>TMC435 100 mg 24 Wks + PR48</arm_group_label>
    <arm_group_label>TMC435 100 mg 48 Wks + PR48</arm_group_label>
    <arm_group_label>TMC435 150 mg 12 Wks + PR48</arm_group_label>
    <arm_group_label>TMC435 150 mg 24 Wks + PR48</arm_group_label>
    <arm_group_label>TMC435 150 mg 48 Wks + PR48</arm_group_label>
    <arm_group_label>Placebo 48 Wks + PR48</arm_group_label>
    <other_name>COPEGUS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have chronic hepatitis C infection as evidenced by liver biopsy, anti-hepatitis C
             virus (HCV) and HCV RNA positive

          -  Must have chronic hepatitis C infection (genotype 1) with HCV RNA level greater
             than10000 IU/mL

          -  Patient must have failed at least 1 prior course of peg interferon
             (Peg-IFN-alfa-2a)/ribavirin (RBV) therapy (standard treatment)

          -  Must be willing to use 2 effective methods of birth control for up to 7 months after
             last dose of study medication

        Exclusion Criteria:

          -  Has an evidence of decompensated liver disease

          -  Co-infection with any other Hepatitis C virus genotype or co-infection with the human
             immunodeficiency virus (HIV)

          -  Has a medical condition which is a contraindication to Peg-INF or RBV therapy

          -  Have had history of, or any current medical condition which could impact the safety of
             the patient in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tibotec Pharmaceuticals, Ireland Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Tibotec Pharmaceuticals, Ireland</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Laurel</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Concord</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Darlinghurst</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fitzroy</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Lambton Heights</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parkville</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woolloongabba N/A</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roeselare</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Creteil N/A</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris Cedex 12</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt A. M.</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nazareth</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petah Tiqva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ramat-Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zefat</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nordbyhagen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tromsø</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Czeladz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2009</study_first_submitted>
  <study_first_submitted_qc>September 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2009</study_first_posted>
  <results_first_submitted>December 18, 2013</results_first_submitted>
  <results_first_submitted_qc>December 18, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 6, 2014</results_first_posted>
  <disposition_first_submitted>June 20, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>June 20, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 28, 2011</disposition_first_posted>
  <last_update_submitted>May 30, 2014</last_update_submitted>
  <last_update_submitted_qc>May 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>Peginterferon alpha-2a</keyword>
  <keyword>PegIFNalpha-2a</keyword>
  <keyword>RBV</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>Placebo</keyword>
  <keyword>TMC435-TIDP16-C206</keyword>
  <keyword>TMC435-C206</keyword>
  <keyword>TMC435</keyword>
  <keyword>HCV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Simeprevir</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 89 sites in 14 countries.</recruitment_details>
      <pre_assignment_details>A total of 618 participants were screened. Of these, 463 participants were randomized of whom 462 participants started treatment. One participant in the placebo group was 'randomized in error,' did not receive treatment, and was withdrawn from the study due to non-compliance (did not come for visit).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TMC435 100mg 12 Wks + PR48</title>
          <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo with PR for 36 weeks.</description>
        </group>
        <group group_id="P2">
          <title>TMC435 100mg 24 Wks + PR48</title>
          <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed by Placebo with PR for 24 weeks.</description>
        </group>
        <group group_id="P3">
          <title>TMC435 100mg 48 Wks + PR48</title>
          <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
        </group>
        <group group_id="P4">
          <title>TMC435 150mg 12 Wks + PR48</title>
          <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo and PR for 36 weeks.</description>
        </group>
        <group group_id="P5">
          <title>TMC435 150mg 24 Wks + PR48</title>
          <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed Placebo and PR for 24 weeks.</description>
        </group>
        <group group_id="P6">
          <title>TMC435 150mg 48 Wks + PR48</title>
          <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
        </group>
        <group group_id="P7">
          <title>Placebo 48Wks + PR48</title>
          <description>Participants received Placebo once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="66"/>
                <participants group_id="P4" count="66"/>
                <participants group_id="P5" count="68"/>
                <participants group_id="P6" count="65"/>
                <participants group_id="P7" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="58"/>
                <participants group_id="P4" count="61"/>
                <participants group_id="P5" count="63"/>
                <participants group_id="P6" count="61"/>
                <participants group_id="P7" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>(not specified)</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TMC435 100mg 12 Wks + PR48</title>
          <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo with PR for 36 weeks.</description>
        </group>
        <group group_id="B2">
          <title>TMC435 100mg 24 Wks + PR48</title>
          <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed by Placebo with PR for 24 weeks.</description>
        </group>
        <group group_id="B3">
          <title>TMC435 100mg 48 Wks + PR48</title>
          <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
        </group>
        <group group_id="B4">
          <title>TMC435 150mg 12 Wks + PR48</title>
          <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo and PR for 36 weeks.</description>
        </group>
        <group group_id="B5">
          <title>TMC435 150mg 24 Wks + PR48</title>
          <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed Placebo and PR for 24 weeks.</description>
        </group>
        <group group_id="B6">
          <title>TMC435 150mg 48 Wks + PR48</title>
          <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Placebo 48Wks + PR48</title>
          <description>Participants received Placebo once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
            <count group_id="B2" value="65"/>
            <count group_id="B3" value="66"/>
            <count group_id="B4" value="66"/>
            <count group_id="B5" value="68"/>
            <count group_id="B6" value="65"/>
            <count group_id="B7" value="66"/>
            <count group_id="B8" value="462"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.5" lower_limit="20" upper_limit="68"/>
                    <measurement group_id="B2" value="50" lower_limit="20" upper_limit="68"/>
                    <measurement group_id="B3" value="50" lower_limit="22" upper_limit="69"/>
                    <measurement group_id="B4" value="48" lower_limit="20" upper_limit="63"/>
                    <measurement group_id="B5" value="51.5" lower_limit="25" upper_limit="68"/>
                    <measurement group_id="B6" value="50" lower_limit="21" upper_limit="69"/>
                    <measurement group_id="B7" value="50.5" lower_limit="22" upper_limit="66"/>
                    <measurement group_id="B8" value="50" lower_limit="20" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="24"/>
                    <measurement group_id="B8" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="43"/>
                    <measurement group_id="B6" value="48"/>
                    <measurement group_id="B7" value="42"/>
                    <measurement group_id="B8" value="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asia Pacific</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe and Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="49"/>
                    <measurement group_id="B6" value="43"/>
                    <measurement group_id="B7" value="46"/>
                    <measurement group_id="B8" value="313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>North-America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="18"/>
                    <measurement group_id="B7" value="13"/>
                    <measurement group_id="B8" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior PR response</title>
          <description>In the study, “Null Responders” were participants with less than 2 log10 IU/mL reduction in HCV RNA compared to baseline at Week 12 of the previous PegIFNα-2a/b and RBV treatment; “Partial Responders” were participants with a greater than or equal to 2 log10 IU/mL reduction in HCV RNA compared to baseline at Week 12, but not achieving an undetectable HCV RNA at the end of the previous PegIFNα-2a/b and RBV treatment; and “Relapsers” were participants with HCV RNA undetectable at end of the previous treatment with PegIFNα-2a/b and RBV, but detectable HCV RNA within 24 weeks of follow-up.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Null responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="16"/>
                    <measurement group_id="B8" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="22"/>
                    <measurement group_id="B7" value="23"/>
                    <measurement group_id="B8" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relapser</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="27"/>
                    <measurement group_id="B8" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Metavir Score</title>
          <description>A Metavir score is used to interpret the degree of inflammation and fibrosis in a liver biopsy. Below are fibrosis scores graded on a 5-point scale from F0 (no fibrosis) to F4 (cirrhosis).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score F0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score F1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="27"/>
                    <measurement group_id="B7" value="18"/>
                    <measurement group_id="B8" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score F2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="16"/>
                    <measurement group_id="B8" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score F3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="13"/>
                    <measurement group_id="B8" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score F4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Participants Achieving a Sustained Virologic Response at the End of Treatment (EOT) and 24 Weeks After the EOT (SVR24)</title>
        <description>The table below shows the percentage of participants in the overall population with an SVR24, defined as having plasma levels of Hepatitis C Virus ribonucleic acid less than 25 IU/mL undetectable at the EOT and 24 weeks after the EOT.</description>
        <time_frame>Week 72</time_frame>
        <population>Intent-to-treat: Participants who received at least 1 dose of study medication were included.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC435 100mg 12 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo with PR for 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TMC435 100mg 24 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed by Placebo with PR for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>TMC435 100mg 48 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
          <group group_id="O4">
            <title>TMC435 150mg 12 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo and PR for 36 weeks.</description>
          </group>
          <group group_id="O5">
            <title>TMC435 150mg 24 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed Placebo and PR for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>TMC435 150mg 48 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Placebo 48Wks + PR48</title>
            <description>Participants received Placebo once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Achieving a Sustained Virologic Response at the End of Treatment (EOT) and 24 Weeks After the EOT (SVR24)</title>
          <description>The table below shows the percentage of participants in the overall population with an SVR24, defined as having plasma levels of Hepatitis C Virus ribonucleic acid less than 25 IU/mL undetectable at the EOT and 24 weeks after the EOT.</description>
          <population>Intent-to-treat: Participants who received at least 1 dose of study medication were included.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="65"/>
                <count group_id="O7" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.7"/>
                    <measurement group_id="O2" value="66.2"/>
                    <measurement group_id="O3" value="60.6"/>
                    <measurement group_id="O4" value="66.7"/>
                    <measurement group_id="O5" value="72.1"/>
                    <measurement group_id="O6" value="80.0"/>
                    <measurement group_id="O7" value="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Participants With a Greater Than 2 log10 Drop in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Time Points During Treatment</title>
        <description>The table below shows the percentage of participants in each treatment group who achieved a greater than 2 log10 drop in plasma levels of HCV RNA at selected time points during treatment.</description>
        <time_frame>Weeks, 2, 4, 8, and 12</time_frame>
        <population>Intent-to-treat: Participants who received at least 1 dose of study medication were included.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC435 100mg 12 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo with PR for 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TMC435 100mg 24 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed by Placebo with PR for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>TMC435 100mg 48 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
          <group group_id="O4">
            <title>TMC435 150mg 12 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo and PR for 36 weeks.</description>
          </group>
          <group group_id="O5">
            <title>TMC435 150mg 24 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed Placebo and PR for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>TMC435 150mg 48 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Placebo 48Wks + PR48</title>
            <description>Participants received Placebo once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants With a Greater Than 2 log10 Drop in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Time Points During Treatment</title>
          <description>The table below shows the percentage of participants in each treatment group who achieved a greater than 2 log10 drop in plasma levels of HCV RNA at selected time points during treatment.</description>
          <population>Intent-to-treat: Participants who received at least 1 dose of study medication were included.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="65"/>
                <count group_id="O7" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.0"/>
                    <measurement group_id="O2" value="93.8"/>
                    <measurement group_id="O3" value="97.0"/>
                    <measurement group_id="O4" value="100.0"/>
                    <measurement group_id="O5" value="95.6"/>
                    <measurement group_id="O6" value="96.9"/>
                    <measurement group_id="O7" value="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.4"/>
                    <measurement group_id="O2" value="93.8"/>
                    <measurement group_id="O3" value="92.4"/>
                    <measurement group_id="O4" value="97.0"/>
                    <measurement group_id="O5" value="91.2"/>
                    <measurement group_id="O6" value="96.9"/>
                    <measurement group_id="O7" value="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.4"/>
                    <measurement group_id="O2" value="89.2"/>
                    <measurement group_id="O3" value="89.4"/>
                    <measurement group_id="O4" value="93.9"/>
                    <measurement group_id="O5" value="91.2"/>
                    <measurement group_id="O6" value="95.4"/>
                    <measurement group_id="O7" value="57.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9"/>
                    <measurement group_id="O2" value="87.7"/>
                    <measurement group_id="O3" value="84.8"/>
                    <measurement group_id="O4" value="92.4"/>
                    <measurement group_id="O5" value="91.2"/>
                    <measurement group_id="O6" value="92.3"/>
                    <measurement group_id="O7" value="60.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Participants Achieving Plasma Levels of Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Undetectable During Treatment and Follow-up</title>
        <description>The table below shows the percentage of participants in each treatment who achieved plasma HCV RNA levels of &lt;25 IU/mL undetectable at selected time points during treatment and follow-up and at the end of treatment (EOT).</description>
        <time_frame>Weeks, 2, 4, 8, 12, 24, 36, 48, 60, 72 and EOT (up to Week 48)</time_frame>
        <population>Intent-to-treat: Participants who received at least 1 dose of study medication were included.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC435 100mg 12 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo with PR for 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TMC435 100mg 24 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed by Placebo with PR for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>TMC435 100mg 48 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
          <group group_id="O4">
            <title>TMC435 150mg 12 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo and PR for 36 weeks.</description>
          </group>
          <group group_id="O5">
            <title>TMC435 150mg 24 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed Placebo and PR for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>TMC435 150mg 48 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Placebo 48Wks + PR48</title>
            <description>Participants received Placebo once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Achieving Plasma Levels of Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Undetectable During Treatment and Follow-up</title>
          <description>The table below shows the percentage of participants in each treatment who achieved plasma HCV RNA levels of &lt;25 IU/mL undetectable at selected time points during treatment and follow-up and at the end of treatment (EOT).</description>
          <population>Intent-to-treat: Participants who received at least 1 dose of study medication were included.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="65"/>
                <count group_id="O7" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7"/>
                    <measurement group_id="O2" value="18.5"/>
                    <measurement group_id="O3" value="15.2"/>
                    <measurement group_id="O4" value="24.2"/>
                    <measurement group_id="O5" value="32.4"/>
                    <measurement group_id="O6" value="27.7"/>
                    <measurement group_id="O7" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="58.5"/>
                    <measurement group_id="O3" value="53.0"/>
                    <measurement group_id="O4" value="62.1"/>
                    <measurement group_id="O5" value="67.6"/>
                    <measurement group_id="O6" value="66.2"/>
                    <measurement group_id="O7" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3"/>
                    <measurement group_id="O2" value="75.4"/>
                    <measurement group_id="O3" value="77.3"/>
                    <measurement group_id="O4" value="84.8"/>
                    <measurement group_id="O5" value="83.8"/>
                    <measurement group_id="O6" value="83.1"/>
                    <measurement group_id="O7" value="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8"/>
                    <measurement group_id="O2" value="73.8"/>
                    <measurement group_id="O3" value="72.7"/>
                    <measurement group_id="O4" value="80.3"/>
                    <measurement group_id="O5" value="85.3"/>
                    <measurement group_id="O6" value="83.1"/>
                    <measurement group_id="O7" value="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8"/>
                    <measurement group_id="O2" value="75.4"/>
                    <measurement group_id="O3" value="78.8"/>
                    <measurement group_id="O4" value="83.3"/>
                    <measurement group_id="O5" value="86.8"/>
                    <measurement group_id="O6" value="86.2"/>
                    <measurement group_id="O7" value="42.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.8"/>
                    <measurement group_id="O2" value="73.8"/>
                    <measurement group_id="O3" value="78.8"/>
                    <measurement group_id="O4" value="80.3"/>
                    <measurement group_id="O5" value="83.8"/>
                    <measurement group_id="O6" value="81.5"/>
                    <measurement group_id="O7" value="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8"/>
                    <measurement group_id="O2" value="73.8"/>
                    <measurement group_id="O3" value="74.2"/>
                    <measurement group_id="O4" value="75.8"/>
                    <measurement group_id="O5" value="80.9"/>
                    <measurement group_id="O6" value="81.5"/>
                    <measurement group_id="O7" value="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.7"/>
                    <measurement group_id="O2" value="67.7"/>
                    <measurement group_id="O3" value="59.1"/>
                    <measurement group_id="O4" value="66.7"/>
                    <measurement group_id="O5" value="72.1"/>
                    <measurement group_id="O6" value="76.9"/>
                    <measurement group_id="O7" value="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.7"/>
                    <measurement group_id="O2" value="66.2"/>
                    <measurement group_id="O3" value="60.6"/>
                    <measurement group_id="O4" value="66.7"/>
                    <measurement group_id="O5" value="73.5"/>
                    <measurement group_id="O6" value="80.0"/>
                    <measurement group_id="O7" value="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT (up to Week 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.3"/>
                    <measurement group_id="O2" value="78.5"/>
                    <measurement group_id="O3" value="80.3"/>
                    <measurement group_id="O4" value="80.3"/>
                    <measurement group_id="O5" value="83.8"/>
                    <measurement group_id="O6" value="86.2"/>
                    <measurement group_id="O7" value="40.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Participants Achieving Plasma Levels of Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Detectable or Undetectable During Treatment and Follow-up</title>
        <description>The table below shows the percentage of participants in each treatment group who achieved plasma HCV RNA levels below the limit of quantification defined as less than 25 IU/mL (detectable or undetectable) at selected time points during treatment, follow-up, and at the end of treatment (EOT).</description>
        <time_frame>Weeks, 2, 4, 8, 12, 24, 36, 48, 60, 72, and EOT (up to Week 48)</time_frame>
        <population>Intent-to-treat: Participants who received at least 1 dose of study medication were included.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC435 100mg 12 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo with PR for 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TMC435 100mg 24 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed by Placebo with PR for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>TMC435 100mg 48 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
          <group group_id="O4">
            <title>TMC435 150mg 12 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo and PR for 36 weeks.</description>
          </group>
          <group group_id="O5">
            <title>TMC435 150mg 24 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed Placebo and PR for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>TMC435 150mg 48 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Placebo 48Wks + PR48</title>
            <description>Participants received Placebo once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Achieving Plasma Levels of Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Detectable or Undetectable During Treatment and Follow-up</title>
          <description>The table below shows the percentage of participants in each treatment group who achieved plasma HCV RNA levels below the limit of quantification defined as less than 25 IU/mL (detectable or undetectable) at selected time points during treatment, follow-up, and at the end of treatment (EOT).</description>
          <population>Intent-to-treat: Participants who received at least 1 dose of study medication were included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="65"/>
                <count group_id="O7" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.6"/>
                    <measurement group_id="O2" value="55.4"/>
                    <measurement group_id="O3" value="54.5"/>
                    <measurement group_id="O4" value="63.6"/>
                    <measurement group_id="O5" value="60.3"/>
                    <measurement group_id="O6" value="66.2"/>
                    <measurement group_id="O7" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.8"/>
                    <measurement group_id="O2" value="72.3"/>
                    <measurement group_id="O3" value="81.8"/>
                    <measurement group_id="O4" value="86.4"/>
                    <measurement group_id="O5" value="82.4"/>
                    <measurement group_id="O6" value="86.2"/>
                    <measurement group_id="O7" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.9"/>
                    <measurement group_id="O2" value="81.5"/>
                    <measurement group_id="O3" value="84.8"/>
                    <measurement group_id="O4" value="87.9"/>
                    <measurement group_id="O5" value="89.7"/>
                    <measurement group_id="O6" value="87.7"/>
                    <measurement group_id="O7" value="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.9"/>
                    <measurement group_id="O2" value="81.5"/>
                    <measurement group_id="O3" value="83.3"/>
                    <measurement group_id="O4" value="89.4"/>
                    <measurement group_id="O5" value="88.2"/>
                    <measurement group_id="O6" value="89.2"/>
                    <measurement group_id="O7" value="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.8"/>
                    <measurement group_id="O2" value="78.5"/>
                    <measurement group_id="O3" value="80.3"/>
                    <measurement group_id="O4" value="86.4"/>
                    <measurement group_id="O5" value="86.8"/>
                    <measurement group_id="O6" value="89.2"/>
                    <measurement group_id="O7" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8"/>
                    <measurement group_id="O2" value="73.8"/>
                    <measurement group_id="O3" value="78.8"/>
                    <measurement group_id="O4" value="81.8"/>
                    <measurement group_id="O5" value="86.8"/>
                    <measurement group_id="O6" value="84.6"/>
                    <measurement group_id="O7" value="43.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                    <measurement group_id="O2" value="73.8"/>
                    <measurement group_id="O3" value="74.2"/>
                    <measurement group_id="O4" value="78.8"/>
                    <measurement group_id="O5" value="82.4"/>
                    <measurement group_id="O6" value="81.5"/>
                    <measurement group_id="O7" value="40.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.2"/>
                    <measurement group_id="O2" value="67.7"/>
                    <measurement group_id="O3" value="60.6"/>
                    <measurement group_id="O4" value="66.7"/>
                    <measurement group_id="O5" value="72.1"/>
                    <measurement group_id="O6" value="78.5"/>
                    <measurement group_id="O7" value="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.7"/>
                    <measurement group_id="O2" value="66.2"/>
                    <measurement group_id="O3" value="60.6"/>
                    <measurement group_id="O4" value="66.7"/>
                    <measurement group_id="O5" value="73.5"/>
                    <measurement group_id="O6" value="80.0"/>
                    <measurement group_id="O7" value="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT (up to Week 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4"/>
                    <measurement group_id="O2" value="81.5"/>
                    <measurement group_id="O3" value="81.8"/>
                    <measurement group_id="O4" value="89.4"/>
                    <measurement group_id="O5" value="89.7"/>
                    <measurement group_id="O6" value="89.2"/>
                    <measurement group_id="O7" value="47.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Participants Achieving a Rapid Virologic Response (RVR)</title>
        <description>The table below shows the percentage of participants in each treatment group who achieved a RVR, defined as having an undetectable plasma Hepatitis C virus ribonucleic acid level after receiving 4 weeks of treatment.</description>
        <time_frame>Week 4</time_frame>
        <population>Intent-to-treat: Participants who received at least 1 dose of study medication were included.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC435 100mg 12 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo with PR for 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TMC435 100mg 24 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed by Placebo with PR for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>TMC435 100mg 48 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
          <group group_id="O4">
            <title>TMC435 150mg 12 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo and PR for 36 weeks.</description>
          </group>
          <group group_id="O5">
            <title>TMC435 150mg 24 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed Placebo and PR for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>TMC435 150mg 48 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Placebo 48Wks + PR48</title>
            <description>Participants received Placebo once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Achieving a Rapid Virologic Response (RVR)</title>
          <description>The table below shows the percentage of participants in each treatment group who achieved a RVR, defined as having an undetectable plasma Hepatitis C virus ribonucleic acid level after receiving 4 weeks of treatment.</description>
          <population>Intent-to-treat: Participants who received at least 1 dose of study medication were included.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="65"/>
                <count group_id="O7" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="58.5"/>
                    <measurement group_id="O3" value="53.0"/>
                    <measurement group_id="O4" value="62.1"/>
                    <measurement group_id="O5" value="67.6"/>
                    <measurement group_id="O6" value="66.2"/>
                    <measurement group_id="O7" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Participants Achieving an Early Virologic Response (EVR)</title>
        <description>The table below shows the percentage of participants who achieved an EVR, defined as having a greater than or equal to 2 log10 reduction in plasma Hepatitis C virus ribonucleic acid from baseline at Week 12.</description>
        <time_frame>Week 12</time_frame>
        <population>Intent-to-treat: Participants who received at least 1 dose of study medication were included.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC435 100mg 12 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo with PR for 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TMC435 100mg 24 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed by Placebo with PR for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>TMC435 100mg 48 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
          <group group_id="O4">
            <title>TMC435 150mg 12 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo and PR for 36 weeks.</description>
          </group>
          <group group_id="O5">
            <title>TMC435 150mg 24 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed Placebo and PR for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>TMC435 150mg 48 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Placebo 48Wks + PR48</title>
            <description>Participants received Placebo once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Achieving an Early Virologic Response (EVR)</title>
          <description>The table below shows the percentage of participants who achieved an EVR, defined as having a greater than or equal to 2 log10 reduction in plasma Hepatitis C virus ribonucleic acid from baseline at Week 12.</description>
          <population>Intent-to-treat: Participants who received at least 1 dose of study medication were included.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="65"/>
                <count group_id="O7" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9"/>
                    <measurement group_id="O2" value="87.7"/>
                    <measurement group_id="O3" value="84.8"/>
                    <measurement group_id="O4" value="92.4"/>
                    <measurement group_id="O5" value="91.2"/>
                    <measurement group_id="O6" value="92.3"/>
                    <measurement group_id="O7" value="60.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)</title>
        <description>The table below shows the percentage of participants in each treatment group who had a cEVR, defined as having undetectable plasma levels of Hepatitis C virus ribonucleic acid at Week 12.</description>
        <time_frame>Week 12</time_frame>
        <population>Intent-to-treat: Participants who received at least 1 dose of study medication were included.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC435 100mg 12 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo with PR for 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TMC435 100mg 24 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed by Placebo with PR for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>TMC435 100mg 48 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
          <group group_id="O4">
            <title>TMC435 150mg 12 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo and PR for 36 weeks.</description>
          </group>
          <group group_id="O5">
            <title>TMC435 150mg 24 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed Placebo and PR for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>TMC435 150mg 48 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Placebo 48Wks + PR48</title>
            <description>Participants received Placebo once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)</title>
          <description>The table below shows the percentage of participants in each treatment group who had a cEVR, defined as having undetectable plasma levels of Hepatitis C virus ribonucleic acid at Week 12.</description>
          <population>Intent-to-treat: Participants who received at least 1 dose of study medication were included.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="65"/>
                <count group_id="O7" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8"/>
                    <measurement group_id="O2" value="73.8"/>
                    <measurement group_id="O3" value="72.7"/>
                    <measurement group_id="O4" value="80.3"/>
                    <measurement group_id="O5" value="85.3"/>
                    <measurement group_id="O6" value="83.1"/>
                    <measurement group_id="O7" value="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)</title>
        <description>The table below shows the percentage of participants in the overall population who achieved undetectable plasma Hepatitis C virus ribonucleic acid levels at the end of treatment (EOT) and 12 Weeks after the planned EOT.</description>
        <time_frame>Week 60</time_frame>
        <population>Intent-to-treat: Participants who received at least 1 dose of study medication were included.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC435 100mg 12 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo with PR for 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TMC435 100mg 24 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed by Placebo with PR for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>TMC435 100mg 48 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
          <group group_id="O4">
            <title>TMC435 150mg 12 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo and PR for 36 weeks.</description>
          </group>
          <group group_id="O5">
            <title>TMC435 150mg 24 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed Placebo and PR for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>TMC435 150mg 48 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Placebo 48Wks + PR48</title>
            <description>Participants received Placebo once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)</title>
          <description>The table below shows the percentage of participants in the overall population who achieved undetectable plasma Hepatitis C virus ribonucleic acid levels at the end of treatment (EOT) and 12 Weeks after the planned EOT.</description>
          <population>Intent-to-treat: Participants who received at least 1 dose of study medication were included.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="65"/>
                <count group_id="O7" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.7"/>
                    <measurement group_id="O2" value="67.7"/>
                    <measurement group_id="O3" value="60.6"/>
                    <measurement group_id="O4" value="66.7"/>
                    <measurement group_id="O5" value="72.1"/>
                    <measurement group_id="O6" value="80.0"/>
                    <measurement group_id="O7" value="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Participants With Viral Breakthrough</title>
        <description>The table below shows the percentage of participants in the overall population in each treatment group during the treatment period who experienced viral breakthrough, defined as a confirmed increase of greater than 1 log10 IU/mL in Hepatitis C virus (HCV) ribonucleic acid (RNA) from the lowest level reached or a confirmed HCV RNA of &gt; 100 IU/mL in participants whose HCV RNA had previously been below the lower limit of quantification (i.e., less than 25 IU/mL detectable or undetectable).</description>
        <time_frame>EOT (up to Week 48)</time_frame>
        <population>Intent-to-treat: Participants who received at least 1 dose of study medication were included.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC435 100mg 12 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo with PR for 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TMC435 100mg 24 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed by Placebo with PR for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>TMC435 100mg 48 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
          <group group_id="O4">
            <title>TMC435 150mg 12 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo and PR for 36 weeks.</description>
          </group>
          <group group_id="O5">
            <title>TMC435 150mg 24 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed Placebo and PR for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>TMC435 150mg 48 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Placebo 48Wks + PR48</title>
            <description>Participants received Placebo once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants With Viral Breakthrough</title>
          <description>The table below shows the percentage of participants in the overall population in each treatment group during the treatment period who experienced viral breakthrough, defined as a confirmed increase of greater than 1 log10 IU/mL in Hepatitis C virus (HCV) ribonucleic acid (RNA) from the lowest level reached or a confirmed HCV RNA of &gt; 100 IU/mL in participants whose HCV RNA had previously been below the lower limit of quantification (i.e., less than 25 IU/mL detectable or undetectable).</description>
          <population>Intent-to-treat: Participants who received at least 1 dose of study medication were included.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="65"/>
                <count group_id="O7" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6"/>
                    <measurement group_id="O2" value="13.8"/>
                    <measurement group_id="O3" value="13.6"/>
                    <measurement group_id="O4" value="9.1"/>
                    <measurement group_id="O5" value="10.3"/>
                    <measurement group_id="O6" value="7.7"/>
                    <measurement group_id="O7" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Participants With Viral Relapse</title>
        <description>The table below shows the percentage of participants in the overall population who had viral relapse, defined as confirmed detectable Hepatitis C virus (HCV) ribonucleic acid (RNA) during the follow-up period in participants with HCV RNA less than 25 IU/mL undetectable at end of treatment.</description>
        <time_frame>Up to Week 72</time_frame>
        <population>Intent-to-treat: Participants who received at least 1 dose of study medication were included.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC435 100mg 12 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo with PR for 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TMC435 100mg 24 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed by Placebo with PR for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>TMC435 100mg 48 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
          <group group_id="O4">
            <title>TMC435 150mg 12 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo and PR for 36 weeks.</description>
          </group>
          <group group_id="O5">
            <title>TMC435 150mg 24 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed Placebo and PR for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>TMC435 150mg 48 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Placebo 48Wks + PR48</title>
            <description>Participants received Placebo once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants With Viral Relapse</title>
          <description>The table below shows the percentage of participants in the overall population who had viral relapse, defined as confirmed detectable Hepatitis C virus (HCV) ribonucleic acid (RNA) during the follow-up period in participants with HCV RNA less than 25 IU/mL undetectable at end of treatment.</description>
          <population>Intent-to-treat: Participants who received at least 1 dose of study medication were included.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="65"/>
                <count group_id="O7" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3"/>
                    <measurement group_id="O2" value="13.7"/>
                    <measurement group_id="O3" value="18.0"/>
                    <measurement group_id="O4" value="11.8"/>
                    <measurement group_id="O5" value="14.0"/>
                    <measurement group_id="O6" value="5.5"/>
                    <measurement group_id="O7" value="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants Who Achieved Normalized Alanine Aminotransferase (ALT) Levels at the End of Treatment (EOT)</title>
        <description>The table below shows the number of participants with abnormal ALT levels at Baseline who achieved the normal ALT levels at the EOT (up to Week 48).</description>
        <time_frame>EOT (up to Week 48)</time_frame>
        <population>Intent-to-treat: Participants who received at least 1 dose of study medication were included.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC435 100mg 12 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo with PR for 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TMC435 100mg 24 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed by Placebo with PR for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>TMC435 100mg 48 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
          <group group_id="O4">
            <title>TMC435 150mg 12 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo and PR for 36 weeks.</description>
          </group>
          <group group_id="O5">
            <title>TMC435 150mg 24 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed Placebo and PR for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>TMC435 150mg 48 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
          <group group_id="O7">
            <title>All TMC435</title>
            <description>Participants in all 6 TMC435 treatment groups combined.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants Who Achieved Normalized Alanine Aminotransferase (ALT) Levels at the End of Treatment (EOT)</title>
          <description>The table below shows the number of participants with abnormal ALT levels at Baseline who achieved the normal ALT levels at the EOT (up to Week 48).</description>
          <population>Intent-to-treat: Participants who received at least 1 dose of study medication were included.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="43"/>
                <count group_id="O7" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="33"/>
                    <measurement group_id="O7" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentrations of TMC435</title>
        <description>The table below shows median (range) predose plasma concentration (C0h) values and median (range) average steady-state plasma concentration (Css,av) values for TMC435 for participants in each of the 6 TMC435 treatment groups.</description>
        <time_frame>0 (predose, baseline) and 4, 8, 12, and 24 hours post-dose at Weeks 2, 4, 8, 12, 16, 24, and 48</time_frame>
        <population>Participants who received at least 1 dose of study medication with at least 1 post-baseline pharmacokinetic (PK) assessment were included in the PK analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC435 100mg 12 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo with PR for 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TMC435 100mg 24 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed by Placebo with PR for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>TMC435 100mg 48 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
          <group group_id="O4">
            <title>TMC435 150mg 12 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo and PR for 36 weeks.</description>
          </group>
          <group group_id="O5">
            <title>TMC435 150mg 24 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed Placebo and PR for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>TMC435 150mg 48 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentrations of TMC435</title>
          <description>The table below shows median (range) predose plasma concentration (C0h) values and median (range) average steady-state plasma concentration (Css,av) values for TMC435 for participants in each of the 6 TMC435 treatment groups.</description>
          <population>Participants who received at least 1 dose of study medication with at least 1 post-baseline pharmacokinetic (PK) assessment were included in the PK analysis population.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C0h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="380.5" lower_limit="34" upper_limit="3599"/>
                    <measurement group_id="O2" value="411.3" lower_limit="101" upper_limit="6943"/>
                    <measurement group_id="O3" value="529.8" lower_limit="62" upper_limit="4212"/>
                    <measurement group_id="O4" value="1323.5" lower_limit="37" upper_limit="12478"/>
                    <measurement group_id="O5" value="1074.0" lower_limit="110" upper_limit="14303"/>
                    <measurement group_id="O6" value="886.1" lower_limit="150" upper_limit="21825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Css,av</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="691.1" lower_limit="204" upper_limit="3960"/>
                    <measurement group_id="O2" value="770.5" lower_limit="344" upper_limit="7218"/>
                    <measurement group_id="O3" value="892.0" lower_limit="290" upper_limit="4580"/>
                    <measurement group_id="O4" value="1960.9" lower_limit="304" upper_limit="13047"/>
                    <measurement group_id="O5" value="1792.3" lower_limit="532" upper_limit="14892"/>
                    <measurement group_id="O6" value="1606.9" lower_limit="635" upper_limit="22417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24h) for TMC435</title>
        <description>The table below shows the median (range) AUC24h values for TMC435 for participants in each TMC435 treatment group.</description>
        <time_frame>0 (predose, baseline) and 4, 8, 12, and 24 hours post-dose at Weeks 2, 4, 8, 12, 16, 24, and 48</time_frame>
        <population>Participants who received at least 1 dose of study medication with at least 1 post-baseline pharmacokinetic (PK) assessment were included in the PK analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>TMC435 100mg 12 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo with PR for 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TMC435 100mg 24 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed by Placebo with PR for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>TMC435 100mg 48 Wks + PR48</title>
            <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
          <group group_id="O4">
            <title>TMC435 150mg 12 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo and PR for 36 weeks.</description>
          </group>
          <group group_id="O5">
            <title>TMC435 150mg 24 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed Placebo and PR for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>TMC435 150mg 48 Wks + PR48</title>
            <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24h) for TMC435</title>
          <description>The table below shows the median (range) AUC24h values for TMC435 for participants in each TMC435 treatment group.</description>
          <population>Participants who received at least 1 dose of study medication with at least 1 post-baseline pharmacokinetic (PK) assessment were included in the PK analysis population.</population>
          <units>ng.h/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16587.0" lower_limit="4897" upper_limit="95030"/>
                    <measurement group_id="O2" value="18492.5" lower_limit="8252" upper_limit="173240"/>
                    <measurement group_id="O3" value="21409.0" lower_limit="6949" upper_limit="109920"/>
                    <measurement group_id="O4" value="47061.8" lower_limit="7301" upper_limit="313135"/>
                    <measurement group_id="O5" value="43015.0" lower_limit="12777" upper_limit="357415"/>
                    <measurement group_id="O6" value="38564.5" lower_limit="15233" upper_limit="538010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Week 72</time_frame>
      <group_list>
        <group group_id="E1">
          <title>TMC435 100mg 12 Wks + PR48</title>
          <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo with PR for 36 weeks.</description>
        </group>
        <group group_id="E2">
          <title>TMC435 100mg 24 Wks + PR48</title>
          <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed by Placebo with PR for 24 weeks.</description>
        </group>
        <group group_id="E3">
          <title>TMC435 100mg 48 Wks + PR48</title>
          <description>Participants received TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
        </group>
        <group group_id="E4">
          <title>TMC435 150mg 12 Wks + PR48</title>
          <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo and PR for 36 weeks.</description>
        </group>
        <group group_id="E5">
          <title>TMC435 150mg 24 Wks + PR48</title>
          <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed Placebo and PR for 24 weeks.</description>
        </group>
        <group group_id="E6">
          <title>TMC435 150mg 48 Wks + PR48</title>
          <description>Participants received TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
        </group>
        <group group_id="E7">
          <title>Placebo 48Wks + PR48</title>
          <description>Participants received Placebo once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gingival infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pneumonia bordetella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Salpingitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Neurilemmoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Histiocytosis haematophagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Viith nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pelvic adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="63" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="65" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="63" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="63" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="29" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="24" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Clinical Development Manager</name_or_title>
      <organization>Jan-Cil France</organization>
      <email>ClinicalTrialDisclosure@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

